LMR Partners’s PAVmed PAVM Stock Holding History

LMR Partners’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-77	Closed	-$30K	–	1227
2022 Q3	$30K	Hold	77	–	–	﹤0.01%	1138
2022 Q2	$32K	Buy	+77	New	+$37.2K	﹤0.01%	1198

Other funds holding PAVM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

XML Financial Bethesda, Maryland $1.24B AUM 20.4% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

LMR Partners's PAVM Position: Q4 2022 in Review

LMR Partners sold out of PAVmed (PAVM) in Q4 2022, closing a stake of 77 shares — an estimated $30K sold.

LMR Partners first reported a position in PAVM in Q2 2022 and held it in 2 quarters. The position peaked at $32K in Q2 2022. 62 funds tracked by Wall St. Rank hold PAVM as of Q4 2022.

LMR Partners reported no remaining PAVmed position as of Q4 2022 after selling out during the quarter.
LMR Partners sold 77 PAVmed shares in Q4 2022, an estimated $30K.
LMR Partners first reported a position in PAVmed in Q2 2022 and held it in 2 quarters.
LMR Partners's PAVmed position peaked at $32K in Q2 2022.
62 funds tracked by Wall St. Rank held PAVmed as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.